We are excited to announce that we will be presenting at the 3rd Antigen-Specific Immune Tolerance Drug Development conference. We will be discussing AnTolRx's antigen-specific nanoformulation platform for the treatment of autoimmune diseases! Come join us in Boston...
We are excited to attend the 38th annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 13th through the 16th.
We will be attending the symposium "New Frontiers in Therapies for Celiac Disease". Join us at the University of Chicago (Chicago, IL) on November 23, 2019.
Psoriasis is an autoimmune disease that affects over 125 million people worldwide, that is up to 3% of the total population! At AnTolRx, our targeted approach actively promotes immune tolerance by inducing an anti-inflammatory phenotype and thus better treat disease....
ANTOLRX ANNOUNCES PFIZER EXERCISES OPTION TO LICENSE IMMUNE TOLERANCE THERAPY FOR POTENTIAL TREATMENT OF TYPE 1 DIABETES
CAMBRIDGE, Mass., March 5,2019 – AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. (NYSE: PFE) has exercised the option granted under a June 2016 agreement to license an immune...
AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics
CAMBRIDGE, Mass., September 8, 2016—AnTolRx, Inc. announced today that it has signed a Series A funding agreement with Pfizer Inc. (NYSE: PFE), Orion Equity Partners LLC and JDRF, the leading global organization funding type 1 diabetes (T1D) research. The funding...
Francisco J Quintana, AnTolRx’s Scientific Founder, will speak next week at the international AhR meeting in Paris.
Dr. Quintana will present an update on his research into the role of the Aryl hydrocarbon Receptor in human health and disease at the 2018 AhR Symposium, held this year in Paris, France from August 28-31st. AnTolRx scientists will also be attending. The meeting will...
ASweetLife - Nanoparticles May Be Used to Treat Type 1 Diabetes "A couple of weeks ago I sat down with Dr. Francisco Quintana, who runs a lab at Brigham and Women’s Hospital in Boston focused on finding new treatments for autoimmune diseases. In particular, he’s...
Kenison, J.E. et al. PNAS doi: 10.1073/pnas.2016451117. PMID: 33239445 (2020).
The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease.
Rothhammer, V. and Quintana, F. Nat Rev Immunol. (2019)
Goettel, J. et al.
Cell Rep 17, 1318-1329(2016)
Yeste, A. et al.
Sci Signal 9, ra61(2016)
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.
Mascanfroni, I. D. et al.
Nat Immunol 14, 1054–1063 (2013).
Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis.
Yeste, A., Nadeau, M., Burns, E. J., Weiner, H. L. & Quintana, F. J.
Proc Natl Acad Sci USA 109, 11270–11275 (2012).
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis.
Quintana, F. J. et al.
Proc Natl Acad Sci USA 107, 20768–20773 (2010).
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells.
Gandhi, R. et al.
Nat Immunol 11, 846–853 (2010).
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27.
Apetoh, L. et al.
Nat Immunol 11, 854 (2010).
Quintana, F. J. et al.
Nature 453, 65–71 (2008).